1️⃣ Nobel Prize in Medicine (2025): Brunkow, Ramsdell & Sakaguchi — honored for uncovering the role of regulatory T cells (Tregs) in immune tolerance. #nobelprize2025

🚀 FDA approves Cemiplimab (Libtayo) — the first ever adjuvant immunotherapy for high-risk cutaneous squamous cell carcinoma (CSCC). In the phase 3 C-POST trial, Libtayo reduced recurrence risk by 68% (HR 0.32; p < 0.0001) after surgery + RT. A new milestone in adjuvant

Precision beyond age: the Trans-RESPECT study redefines HER2⁺ care for older women. In this prospective–retrospective analysis of the RESPECT trial, HER2DX—a 27-gene assay by Reveal Genomics—proved independently prognostic in women aged 70–80 with early-stage HER2⁺ breast

A major step forward in follicular lymphoma. The #FDA has now granted full approval to epcoritamab-bysp in combination with R², supported by a remarkable PFS benefit (HR 0.21) and an ORR of 89% in R/R FL. #Oncology #Lymphoma #FollicularLymphoma #Hematology #PrecisionOncology

Precision medicine strategy in pancreatic ductal adenocarcinoma - ESMO Open ⁦ESMO - Eur. Oncology⁩ esmoopen.com/article/S2059-…

New NEJM Evidence analysis (Oct 2025) explores how age influences the benefit of treatment intensification (ARPI ± chemotherapy) in metastatic hormone-sensitive prostate cancer (mHSPC). #ProstateCancer #Oncology #NEJM #UroOncology #CancerResearch #PrecisionMedicine

🔵Preoperative PAXG vs mFOLFIRINOX for R or BR pancreatic cancer Full publ. of CASSANDRA trial The Lancet Oncology ➡️PAXG: cisplatin, nab-paclitaxel, capecitabine, and gemcitabine ➡️Design👇 ✅EFS: 16 vs 10.2 mo HR: 0.63 [0.47–0.84]; p=0.0018 ✅G3-4 AE: 66% vs 61% ⏰OS is

FDA has approved perioperative pembrolizumab + enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) based on KEYNOTE-905 / EV-303. #BladderCancer #MIBC #Oncology #FDA #Pembrolizumab #EnfortumabVedotin #Immunotherapy #ADC #KEYNOTE905 #EV303

🔘Response evaluation to systemic therapy in HCC HEPATOLOGY Journal ✅Very useful excellent review ✅Patient-centered approach upon detection of progression by imaging 👉journals.lww.com/hep/abstract/9… #cancer #oncology #MedX #liver OncoAlert

A new study in JCO Clinical Cancer Informatics highlights a major environmental risk factor for melanoma: Intensive agriculture and herbicide exposure. #Melanoma #Toxicology #SkinCancer #Agriculture #PublicHealth #CancerEpidemiology #Oncology #Pesticides #JCO #CancerResearch

FDA has approved perioperative Durvalumab + FLOT for resectable gastric and GEJ adenocarcinoma, based on the MATTERHORN results! A major step forward—immunotherapy enters the curative setting. #FDA #GastricCancer #Oncology #Immunotherapy #Durvalumab #MATTERHORN

A Major Unmet Need in Oncology: Radiation-Induced Lung Injury A new Phase 2 study in The Lancet Oncology (Dec 2025) shows that pirfenidone, added to standard steroids, can meaningfully preserve lung function in patients with radiation-induced lung injury. 🔗

A fascinating new analysis in JAMA Network Open (Nov 2025) highlights a paradox many clinicians recognize but rarely discuss openly: PARP inhibitors dramatically improve PFS… yet OS differences remain blurred. Why? Because in nearly all major trials, crossover allows placebo

Rusya gerçekten “kanser aşısını” buldu mu? Devrim mi, yoksa yeni bir umut sömürüsü mü? İddiaların ve açıklamaların arkasındaki tablo, beklediğimizden çok daha karmaşık. Rusya, mRNA, peptid ve onkolitik virüs tabanlı terapötik kanser aşıları üzerinde gerçek bilimsel çalışmalar

New Evidence on ADT Duration in Prostate Cancer (JAMA Oncology, Nov 2025) A meta-analysis of 10,266 patients shows a clear message. Risk-based approach matters: • 1 intermediate risk factor → 0 months • ≥2 risk factors → ~6 months • High-risk → ~12 months • Very

The MOST-CIRCUIT phase II trial published in JAMA Oncology shows that nivolumab + low-dose ipilimumab achieves a 63% response rate and 71% 6-month PFS in advanced dMMR/MSI-H non-colorectal cancers—a remarkable improvement over historical PD-1 monotherapy. These results suggest

For two decades, p53 was the “undruggable” target. Now we may finally be witnessing the turning point. #ESMOAsia2025 #p53 #Rezatapopt #PrecisionOncology #TargetedTherapy #TP53 #OvarianCancer #OncologyResearch

#SABCS25 delivered one of the strongest collections of practice-changing data we’ve seen in years — reshaping treatment across TNBC, HR+/HER2–, HER2-low/ultralow, and metastatic disease. Here are the Top 10 abstracts that will meaningfully influence real-world oncology:

#SABCS25 Is ctDNA predictive here? Not formally—yet. But studies like this move ctDNA beyond a purely prognostic marker. When ctDNA status is used to guide treatment de-escalation decisions and consistently identifies patients who do not need chemotherapy, the line between

📘Management of Cancer During Pregnancy ASCO Guideline 👉ascopubs.org/doi/pdf/10.120… #cancer #oncology #pregnancy #MedX OncoAlert